Current Opinion in Oncology was launched in 1989. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of psychiatry is divided into 15 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue.
Giuseppe Curigliano, MD PhD, is Associate Professor of Medical Oncology at University of Milan, Italy, and the Head of the Division of Early Drug Development at European Institute of Oncology, Italy. He is a clinician and researcher specializing in early drug development for patients with solid tumors with a special commitment to breast cancer. He has been an ESMO Breast Faculty Member since 2001 and served on the Program Scientific Committee of the St Gallen Conference since 2011, and as Scientific Chair in St Gallen in 2017 and 2019. He has been appointed as Editor of Annals of Oncology for the period 2014–2018 and 2018–2020, and serves as co-Editor-in-Chief of The Breast, co-Editor-in-Chief of Cancer Treatment Reviews, Associate Editor of the European Journal of Cancer, as well as Editor of the Journal of Clinical Oncology and Current Opinion in Oncology. He also serves on the European School of Oncology (ESO) faculty committee.
He served as the scientific chair of the IMPAKT meeting that was held in Brussels in 2014 and as the Breast Cancer (metastatic) Track Chair of the ESMO 2014 meeting in Madrid. He was the co-chair for ESMO Breast Cancer Congress in 2019 and 2020.
Dr Curigliano from August 2020 will be the Chair of the ESMO Guidelines Committee.
Dr Curigliano was awarded with the first ESO Umberto Veronesi Award in Vienna in 2017 and with the Fellowship of the European Academy of Cancer Sciences in Paris in 2017.
He has contributed to over 390 peer-reviewed publications.
Marc Sanson, MD, PhD is Professor at Sorbonne Université, Paris, France. He has an activity of clinical neuro-oncology at the Department of Neurology 2, Pitié-Salpêtrière Hospital in Paris. He is also head of the research team “Genetic and Development of Brain Tumors” at the Paris Brain Institute (Institut du Cerveau -ICM). He is the Director of the “CURAMUS” site of Sorbonne-Université which is one of the eight French Sites for Integrated Research on Cancer (SiRIC).
Dr Sanson has published many research articles on neuro-oncology, including more than 200 dedicated to gliomas, as well as book chapters, and is a frequently requested lecturer on this topic. His main interest is focused on clinical and translational research on gliomas, including novel targeted therapies, germline and somatic genetic characterisation and development of new biomarkers.
He is a reviewer on a number of journals, including the Journal of Clinical Oncology, Nature cancer, Nature Comm, Science Transl Res, Lancet, Lancet Oncology, Annals of Oncology, Annals of Neurology, Neurology, Cancer, Clinical Cancer Research, Cancer Research, Acta Neuropathologica.
Dr Sanson earned his MD at University Paris V-Descartes and his PhD at University Paris VII-Diderot. He completed a residency in Neurology in Paris, and a post-doctoral stage at McGill University, Canada.
Miguel A. Sanz
Dr Miguel A. Sanz is Researcher Emeritus of the Instituto de Investigación Sanitaria La Fe, Spain, and Honorary Professor of the Department of Medicine at the University of Valencia, Spain. After earning his medical degree at the University of Salamanca in Spain, he was intern, resident and subsequently completed a fellowship in Hematology at the University Hospital La Fe.
He was appointed as Head of the Clinical Hematology Section to the University Hospital La Fe in 1977 and then later promoted to Head of the Hematology Department in 2007 as well as Full Professor of Medicine at the University of Valencia.
Professor Sanz is Chairman of the Spanish PETHEMA Group and leads the Working Parties of acute promyelocytic leukemia and infections in neutropenic patients. He is currently a reviewer for numerous high-profile medical journals, including all top hematology journals, and has authored more than 580 peer-reviewed papers, numerous book chapters, and in excess of 1100 abstracts at national and international meetings. Prof. Sanz has also lectured widely in Europe, North, central and South America, as well as in the Middle East and Asia, serving as lecturer at the American Society of Hematology and European Hematology Association meetings in several occasions.